RxDoctor Payments Data

Robert Boughan, MD

Internal Medicine · Lutherville, MDNPI 1770608721

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 70 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$536
  • Merck$132
  • Lilly USA, LLC$123
  • Novo Nordisk$53
  • Teva Pharmaceuticals USA, Inc.$37
  • Johnson & Johnson$29
  • plus $159 from 10 others

What the payments were for

  • Food & beverage$1,05699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,069 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$169,967
Medicare patients
500
Services billed
1,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$99,206
MounjaroTirzepatide43$67,461
EliquisApixaban57$67,019
JardianceEmpagliflozin31$48,818
FarxigaDapagliflozin Propanediol32$40,780
XareltoRivaroxaban23$34,618
LinzessLinaclotide26$32,360
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$31,951
ZavzpretZavegepant Hcl12$14,790
Atorvastatin Calcium485$6,646
Rosuvastatin Calcium230$4,975
SynthroidLevothyroxine Sodium57$4,035
Losartan Potassium272$3,682
Pravastatin Sodium120$3,228
Epinephrine16$2,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$99,20676 claims
PfizerEliquis, Zavzpret$25$81,80969 claims
Lilly USA, LLCMounjaro$123$67,46143 claims
Boehringer IngelheimJardiance$12$48,81831 claims
AstraZenecaFarxiga$536$40,78032 claims
AbbVieLinzess, Synthroid$13$36,39583 claims
Johnson & JohnsonXarelto$29$34,61823 claims
Hikma Pharmaceuticals USAEpinephrine$11$2,34016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →